Trial HIV vaccine triggers elusive and essential antibodies, pointing the way toward a successful vaccine

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

​Medical Xpress – latest medical and health news stories

​Read More